Impact of Resveratrol and Pharmaceutical Care on Type 2 Diabetes Mellitus and Its Neuropathic Complication: A Randomized Placebo Controlled Clinical Trial

Figure 2

Monthly fluctuations in the number of DTPs main categories during 90 days. Follow-up and/or intervention medication profiles in the four groups: (a) Resv, (b) Placebo, (c) Resv + PC, and (d) Placebo + PC groups. Resv, resveratrol; PC, pharmaceutical care; DTP, drug therapy problem.

(a)

(b)

(c)

(d)